(0.25%) 5 144.25 points
(0.14%) 38 494 points
(0.41%) 17 920 points
(-0.64%) $83.31
(2.24%) $1.966
(-0.12%) $2 344.30
(0.02%) $27.54
(2.85%) $948.35
(-0.06%) $0.934
(-0.10%) $11.01
(-0.29%) $0.798
(1.88%) $93.60
Live Chart Being Loaded With Signals
Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally...
Stats | |
---|---|
本日の出来高 | 26 688.00 |
平均出来高 | 43 979.00 |
時価総額 | 1.59B |
EPS | $0 ( 2024-01-25 ) |
次の収益日 | ( $0.310 ) 2024-05-28 |
Last Dividend | $12.81 ( 2018-12-10 ) |
Next Dividend | $0 ( N/A ) |
P/E | 34.75 |
ATR14 | $0.0200 (0.05%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2011-01-18 | Sun Pharmaceutical Industries Ltd | Buy | 712 500 | Restricted Shares |
2011-01-18 | Sun Pharmaceutical Industries Ltd | Buy | 712 500 | Restricted Shares |
2011-01-18 | Sun Pharmaceutical Industries Ltd | Sell | 712 500 | Warrant (right to buy) |
2010-11-04 | Sun Pharmaceutical Industries Ltd | Buy | 5 159 765 | Ordinary Shares |
2010-11-01 | Franklin Resources Inc | Sell | 5 159 765 | Ordinary Shares |
INSIDER POWER |
---|
0.00 |
Last 84 transactions |
Buy: 16 575 249 | Sell: 25 681 902 |
ボリューム 相関
Taro Pharmaceutical 相関
10 最も正の相関 |
---|
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Taro Pharmaceutical 相関 - 通貨/商品
Taro Pharmaceutical 財務諸表
Annual | 2023 |
収益: | $572.95M |
総利益: | $268.32M (46.83 %) |
EPS: | $0.680 |
FY | 2023 |
収益: | $572.95M |
総利益: | $268.32M (46.83 %) |
EPS: | $0.680 |
FY | 2022 |
収益: | $561.35M |
総利益: | $293.12M (52.22 %) |
EPS: | $1.550 |
FY | 2021 |
収益: | $548.97M |
総利益: | $296.66M (54.04 %) |
EPS: | $-10.12 |
Financial Reports:
No articles found.
Taro Pharmaceutical Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $12.81 | 2018-12-10 |
Last Dividend | $12.81 | 2018-12-10 |
Next Dividend | $0 | N/A |
Payout Date | 2018-12-28 | |
Next Payout Date | N/A | |
# dividends | 1 | -- |
Total Paid Out | $12.81 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 1.22 | -- |
Div. Sustainability Score | 5.86 | |
Div.Growth Potential Score | 2.19 | |
Div. Directional Score | 4.03 | -- |
Year | Amount | Yield |
---|---|---|
2018 | $12.81 | 12.40% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
With a moderate Dividend Sustainability Score (DSS), the company may sustain its dividends, but continuous monitoring is advised for any financial shifts. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
LOMA | Dividend Knight | 2023-06-30 | Quarterly | 2 | 5.23% | 8.53 |
VGI | Dividend Royal | 2024-02-09 | Monthly | 13 | 7.36% | 8.50 |
PHK | Dividend Royal | 2023-11-10 | Monthly | 22 | 6.88% | 8.50 |
KIO | Dividend Royal | 2023-12-14 | Monthly | 12 | 7.05% | 8.50 |
GOF | Dividend Royal | 2023-11-14 | Monthly | 18 | 8.03% | 8.50 |
PCF | Dividend King | 2023-12-18 | Monthly | 38 | 7.05% | 8.50 |
PVL | Dividend King | 2023-11-15 | Monthly | 14 | 9.37% | 8.50 |
NCV | Dividend Royal | 2024-02-09 | Monthly | 22 | 7.68% | 8.50 |
SBR | Dividend Royal | 2023-11-14 | Monthly | 38 | 7.74% | 8.50 |
MTR | Dividend Diamond | 2023-10-30 | Monthly | 39 | 10.10% | 8.50 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.0748 | 1.500 | 8.50 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0211 | 1.200 | 9.30 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.0261 | 1.500 | -0.821 | -1.231 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 3.60 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 3.03 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 1.022 | 1.500 | 5.43 | 8.15 | [0.2 - 2] |
debtRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 0.6] |
interestCoverageTTM | -2.55 | 1.000 | -2.05 | -2.05 | [3 - 30] |
operatingCashFlowPerShareTTM | 3.80 | 2.00 | 8.73 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 2.29 | 2.00 | 8.86 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 2.5] |
grossProfitMarginTTM | 0.480 | 1.000 | 5.33 | 5.33 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.0360 | 1.000 | -1.280 | -1.280 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0 | 1.000 | -1.111 | -1.111 | [0.2 - 2] |
assetTurnoverTTM | 0.282 | 0.800 | -1.451 | -1.161 | [0.5 - 2] |
Total Score | 5.86 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 34.87 | 1.000 | 6.58 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0261 | 2.50 | -0.528 | -1.231 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 2.29 | 2.00 | 9.24 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 3.80 | 2.00 | 8.73 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -0.769 | 1.500 | -8.46 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.234 | 1.000 | 6.65 | 0 | [0.1 - 0.5] |
Total Score | 2.19 |
Taro Pharmaceutical
Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally. The company also develops and manufactures active pharmaceutical ingredients primarily for use in its finished dosage form products. It offers its products for various therapeutic categories comprising allergy, analgesic, antibacterial, antibiotic, anticonvulsant, antiemetic, antifungal, anti-inflammatory, anti-cancer, antiplatelet agent, antipyretic, cardiovascular, CNS, corticosteroid, cosmetic, cough and cold, dermatology, diuretic, endocrine, gastrointestinal, laxative, narcotics, neuropathic pain, neuropsychiatric, sedative/hypnotic, and topical anti-neoplastic. The company provides its products in the form of capsule, cream, drops, emulsion, gel/gel kit, granules, injectable, lotion, oil, ointment, paste, powder/powder for solution, rectal suppository, shampoo, solution/solution for infusion, spray, suspension, syrup, tablets, toothpaste and mouthwash, topical foam, and topical solution. It distributes and sells its products directly to wholesalers, retail drug store chains, food chains, hospitals, mass merchandisers, grocery chains, and other direct purchasers and customers, as well as healthcare institutions and private pharmacies. The company was founded in 1950 and is based in Haifa, Israel. Taro Pharmaceutical Industries Ltd. is a subsidiary of Alkaloida Chemical Company Exclusive Group Ltd.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。